Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Western blot [1]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-11430 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- APOBEC3B Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Vial size
- 400 µL
- Concentration
- 2 mg/mL
- Storage
- -20° C, Avoid Freeze/Thaw Cycles
Submitted references Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment.
APOBEC3 Mediates Resistance to Oncolytic Viral Therapy.
Evgin L, Huff AL, Kottke T, Thompson J, Molan AM, Driscoll CB, Schuelke M, Shim KG, Wongthida P, Ilett EJ, Smith KK, Harris RS, Coffey M, Pulido JS, Pandha H, Selby PJ, Harrington KJ, Melcher A, Vile RG
Cancer immunology research 2019 May;7(5):828-840
Cancer immunology research 2019 May;7(5):828-840
APOBEC3 Mediates Resistance to Oncolytic Viral Therapy.
Huff AL, Wongthida P, Kottke T, Thompson JM, Driscoll CB, Schuelke M, Shim KG, Harris RS, Molan A, Pulido JS, Selby PJ, Harrington KJ, Melcher A, Evgin L, Vile RG
Molecular therapy oncolytics 2018 Dec 21;11:1-13
Molecular therapy oncolytics 2018 Dec 21;11:1-13
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis using an APOBEC3B polyclonal antibody (Product # PA5-11430) in mouse testis tissue lysates (35 µg per lane).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
